Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , Jan. 2, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Illumina, Inc. (NASDAQ: ILMN) between May 1, 2023 and October 16, 2023, both dates inclusive (the "Class Period"), of the important January 9, 2024 lead plaintiff deadline. SO WHAT: If you purchased Illumina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action - ILMN

Albemarle

Bristol-Myers

Conagra Brands

Dollar General

Devon Energy

Estee Lauder

Enphase Energy

Eversource Energy

Etsy

Hormel Foods

Moderna

NextEra Energy

Paycom Software

Pfizer

Insulet

V.F.

Walgreens

The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.

Here are the 20 worst-performing stocks among the S&P 500 in 2023

Allstate

Arista Networks

Carnival

Chipotle

Centene

Catalent

Expedia

Intel

NVIDIA

Warner Bros Discovery Inc

Zions Bancorp

Talk about a strong finish. Investors who hung onto the top S&P 500 stocks this year ended up much richer for the effort.

12 Stocks Turn $10,000 Into $320,800 In 12 Months

Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.

Here's Why You Should Retain Illumina (ILMN) Stock for Now

LOS ANGELES , Dec. 28, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Illumina, Inc. ("Illumina" or the "Company") (NASDAQ: ILMN ). Class Period: September 21, 2020 – November 9, 2023 Lead Plaintiff Deadline: January 9, 2024 If you wish to serve as lead plaintiff of the Illumina lawsuit, you can submit your contact information at www.glancylaw.com/cases/Illumina-Inc-1/.

ILMN Investors Have Opportunity to Lead Illumina, Inc. Securities Fraud Lawsuit

If you suffered losses exceeding $100,000 investing in Illumina securities between September 21, 2020 and November 9, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ILMN.

ILLUMINA INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Illumina To Contact Him Directly To Discuss Their Options

RADNOR, Pa. , Dec. 26, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Illumina, Inc. ("Illumina") (NASDAQ: ILMN).

Important January 9, 2024 Deadline Reminder for Illumina, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Illumina, Inc. (ILMN) Investors of Securities Fraud Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action lawsuit for violations of the federal securities laws in the U.S. District Court for the Southern District of California against Illumina, Inc. (“Illumina” or the “Company”) and certain of the Company's current and former senior executives (collectively, “Defendants”) on behalf of investors who purchased or otherwise acquired Illumina common stock.

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Illumina, Inc.

Activist investor Carl Icahn said on Monday that he plans to oust directors at Illumina, laying the groundwork for a second board challenge at the gene-sequencing company months after shareholders elected one of his director candidates.

Activist Icahn prepares a second board challenge at Illumina -letter

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Illumina, Inc. ("Illumina" or the "Company") (NASDAQ: ILMN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Illumina, Inc. - ILMN

The saga over DNA sequencing firm Illumina Inc.'s (ILMN) controversial purchase of cancer diagnostic test maker GRAIL appears to be over.

Illumina Gives Up Fight With Regulators, Will Divest GRAIL

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Illumina, Inc. (“Illumina”) (NASDAQ: ILMN). The action charges Illumina with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a r.

Kessler Topaz Meltzer & Check, LLP Reminds Illumina, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm

Activist investor Carl Icahn said on Monday that he plans to oust directors at Illumina, signalling plans to mount a second board challenge at the gene-sequencing company only months after shareholders elected one of his director candidates.

Icahn aims to remove Illumina's legacy directors - letter

After over two years of antitrust battles, Illumina Inc (NASDAQ:ILMN) will sell its cancer diagnostic test maker Grail through a third-party sale of capital markets transaction by the second quarter next year.

Illumina Stock Rises After Sale of Grail

Illumina stock rose Monday after the company said it would divest its cancer detection outfit, Grail, following a lengthy court battle.

Illumina Stock Rises On Plans To Divest Controversial Buyout Grail

Roku

Here's our daily look at three charts connected to recent news-driven price moves, with key technical levels to monitor.

3 Charts For Investors to Watch Monday: Illumina, Roku, Bitcoin

Illumina Inc (NASDAQ:ILMN) stock traded on the front foot, up 5.6% to $134.25, after the company told investors it will seek a sale of its gene sequencing business Grail. It comes after European antitrust regulator, the European Commission, gave the Illumina twelve-months to sell the company it bought in 2021 for $7.1 billion.

Illumina shares rally as it puts Grail up for sale

Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and European antitrust enforcers for more than two years and faced fierce opposition from activist investor Carl Icahn.

Illumina to divest cancer test maker Grail after antitrust battles

The decision shows the company didn't see a way to overcome regulators' objections.

Illumina to Sell Grail. It's Giving Up on its Biotech Antitrust Battle.

Illumina Inc. said Sunday it will sell its Grail unit, after a federal appeals court on Friday found the $7.1 billion acquisition in 2021 to be anticompetitive.

Illumina to sell cancer-test maker Grail after latest antitrust ruling

The divestiture will be executed through a third-party sale or capital markets transaction, San Diego-based Illumina said in a statement, adding that it would finalize the terms by second quarter of 2024.

Illumina to divest cancer test maker Grail

Illumina said Sunday it will the sell cancer detection startup after a U.S. appeals court said the $7.1 billion deal violated antitrust laws,

Illumina To Sell Grail After U.S. Antitrust Ruling

SAN DIEGO , Dec. 17, 2023 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL. The divestiture will be executed through a third-party sale or capital markets transaction, consistent with the European Commission's divestiture order, with the goal of finalizing the terms by the end of the second quarter of 2024.

Illumina Announces Decision to Divest GRAIL

NEW YORK , Dec. 16, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Illumina, Inc. (NASDAQ: ILMN) between May 1, 2023 and October 16, 2023, both dates inclusive (the "Class Period"), of the important January 9, 2024 lead plaintiff deadline. SO WHAT: If you purchased Illumina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ILMN

Judges also fault agency for not properly considering Illumina's plan to fix drawbacks.

News for Illumina Stock (ILMN)